Mano Roy, Vertosick Emily A, Hakimi Abraham Ari, Sternberg Itay A, Sjoberg Daniel D, Bernstein Melanie, Dalbagni Guido, Coleman Jonathan A, Russo Paul
Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
Urol Oncol. 2016 May;34(5):239.e1-8. doi: 10.1016/j.urolonc.2015.12.001. Epub 2016 Jan 12.
Delaying nephrectomy<3 months does not adversely affect treatment outcome of renal tumors. Whether surgical waiting time (SWT; time from diagnosis to surgery)>3 months affects treatment outcome for large renal masses has not been well studied. We aimed to evaluate if SWT is associated with treatment outcome of renal masses >4cm and identify patients who are more likely to experience prolonged SWT.
Data from 1,484 patients undergoing radical or partial nephrectomy at a single institution for a nonmetastatic renal mass>4cm between 1995 and 2013 were reviewed. Patients with benign tumors and incomplete preoperative data were excluded. The association between SWT and disease upstaging at the time of surgery and recurrence at 2 and 5 years was assessed using logistic regression. Cancer-specific survival (CSS) and overall survival were assessed with landmark survival analyses and multivariable Cox proportional hazards models. All analyses were adjusted for patient and tumor characteristics.
Of the final cohort of 1,278 patients, 267 (21%) had SWT>3 months. Patients with larger, symptomatic tumors had shorter SWT. Median follow-up for survivors was 3.8 years (interquartile range: 1.5-7.4). On multivariable analysis, SWT was not associated with disease upstaging, recurrence, or CSS. Longer SWT was associated with decreased overall survival (hazard ratio = 1.17; 95% CI: 1.08-1.27; P = 0.0002). Sex and tumor size, histology, and presentation were associated with disease upstaging, recurrence, and CSS. The most common cause for surgical delay>3 months was evaluation and treatment of comorbidities.
Patient and tumor characteristics, rather than SWT, were associated with disease upstaging, recurrence, and CSS, and should guide the decision to delay surgery when treating nonmetastatic renal tumors>4cm.
将肾切除术推迟至<3个月对肾肿瘤的治疗结果并无不利影响。手术等待时间(SWT;从诊断到手术的时间)>3个月是否会影响大型肾肿块的治疗结果尚未得到充分研究。我们旨在评估SWT是否与直径>4cm的肾肿块的治疗结果相关,并确定更有可能经历较长SWT的患者。
回顾了1995年至2013年间在单一机构接受根治性或部分肾切除术的1484例患者的数据,这些患者患有直径>4cm的非转移性肾肿块。排除患有良性肿瘤和术前数据不完整的患者。使用逻辑回归评估SWT与手术时疾病分期升级以及2年和5年复发之间的关联。通过标志性生存分析和多变量Cox比例风险模型评估癌症特异性生存(CSS)和总生存。所有分析均针对患者和肿瘤特征进行了调整。
在最终的1278例患者队列中,267例(21%)的SWT>3个月。肿瘤较大且有症状的患者SWT较短。幸存者的中位随访时间为3.8年(四分位间距:1.5 - 7.4)。在多变量分析中,SWT与疾病分期升级、复发或CSS无关。较长的SWT与总生存降低相关(风险比 = 1.17;95%可信区间:1.08 - 1.27;P = 0.0002)。性别、肿瘤大小、组织学和临床表现与疾病分期升级、复发和CSS相关。手术延迟>3个月的最常见原因是合并症的评估和治疗。
患者和肿瘤特征而非SWT与疾病分期升级、复发和CSS相关,在治疗直径>4cm的非转移性肾肿瘤时,应指导手术延迟的决策。